The natural history of COVID-19 in vaccinated inflammatory bowel disease patients

[1]  A. Amiot,et al.  The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study , 2022, Journal of Crohn's & colitis.

[2]  M. Dalamaga,et al.  Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges , 2022, Metabolism Open.

[3]  M. Parkes,et al.  COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study , 2022, The Lancet Gastroenterology & Hepatology.

[4]  S. Sebastian,et al.  Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis , 2022, Clinical Gastroenterology and Hepatology.

[5]  S. Zeger,et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.

[6]  C. Liatsos,et al.  Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease , 2022, Journal of clinical medicine.

[7]  Jiannan Li,et al.  Treatment of Inflammatory Bowel Disease: A Comprehensive Review , 2021, Frontiers in Medicine.

[8]  J. Sauk,et al.  COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2021, Inflammatory bowel diseases.

[9]  P. Balestrieri,et al.  Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS‐CoV‐2 infection: an IG‐IBD study , 2021, Alimentary pharmacology & therapeutics.

[10]  S. Ng,et al.  Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of More Than 6000 Patients From an International Registry , 2021, Gastroenterology.

[11]  G. Michalopoulos,et al.  The natural history of COVID-19 in patients with inflammatory bowel disease: a nationwide study by the Hellenic Society for the study of IBD , 2021, European journal of gastroenterology & hepatology.

[12]  M. Kappelman,et al.  The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry , 2021, Journal of Crohn's & colitis.

[13]  C. Lees,et al.  Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD , 2021, Gut.

[14]  L. Peyrin-Biroulet,et al.  SARS-CoV-2 vaccination in IBD: more pros than cons , 2021, Nature Reviews Gastroenterology & Hepatology.

[15]  M. Dubinsky,et al.  SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting , 2021, Gut.

[16]  K. To,et al.  Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic , 2021, Emerging microbes & infections.

[17]  A. Hart,et al.  Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce , 2020, Journal of Crohn's & colitis.

[18]  S. Ng,et al.  Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient , 2020, Alimentary pharmacology & therapeutics.

[19]  Philip Smith,et al.  British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic , 2020, Gut.

[20]  D. Rubin,et al.  AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary , 2020, Gastroenterology.

[21]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[22]  D. Rubin,et al.  Real-World Experience with Tofacitinib in IBD at a Tertiary Center , 2019, Digestive Diseases and Sciences.

[23]  S. Travis,et al.  Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease , 2017, Alimentary pharmacology & therapeutics.

[24]  P. Rutgeerts,et al.  The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.

[25]  S. Lv,et al.  Anti‐TNF‐α therapy for patients with sepsis: a systematic meta‐analysis , 2014, International journal of clinical practice.

[26]  Xiaomei Zhang,et al.  Differential expression of adhesion molecules and chemokines between nasal and small intestinal mucosae: implications for T‐ and sIgA+ B‐lymphocyte recruitment , 2007, Immunology.

[27]  P. Rutgeerts,et al.  IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. , 2019, Journal of Crohn's & colitis.

[28]  P. Tüll,et al.  European Centre for Disease Prevention and Control , 2006 .